Bambusa Therapeutics Files For Nasdaq IPO To Fund Bispecific Antibody Pipeline

Bambusa Therapeutics, Inc. (BBTX) has filed for an initial public offering to list its common stock on the Nasdaq Global Select Market. The clinical-stage biopharmaceutical company plans to use the proceeds to advance its pipeline of long-acting bispecific antibodies, which target immunology and inflammation diseases.

The Boston-based company currently has two lead clinical programs. Its main candidate, BBT001, is undergoing Phase 1/2 proof-of-concept studies for atopic dermatitis and other skin conditions. The second candidate, BBT002, is being developed for respiratory diseases like asthma and chronic obstructive pulmonary disease, having already demonstrated favorable safety in healthy volunteers. Bambusa also has two preclinical programs targeting inflammatory bowel disease and autoimmune disorders.

As a clinical-stage biotech, Bambusa does not currently generate revenue and is operating at a loss. The company reported a net loss of $41.1 million in 2025 and a net loss of $22.4 million for the first six months of 2026. The funds raised from the offering will primarily support Phase 2b clinical trials for both BBT001 and BBT002, as well as preclinical development and general corporate activities.

Investors will want to watch the upcoming clinical readouts from the ongoing Phase 1/2 trials of BBT001. Progress in advancing the preclinical candidates, BBT003 and BBT004, toward first-in-human studies planned for 2026 and 2027 will also be key milestones for the company as it seeks to capture a share of the rapidly growing immunology and inflammation market.